- 1 Title
- 2 Criteria to Achieve Safe Antimicrobial Intravenous-to-Oral Switch in Hospitalised Adult Populations:
- 3 A Systematic Rapid Review
- 4 Author Information
- 5 Eleanor J Harvey<sup>1</sup>, Monsey McLeod<sup>2</sup>, Caroline De Brún<sup>3</sup>, Diane Ashiru-Oredope<sup>1,4</sup>\*
- 6 Affiliations
- 7 <sup>1</sup>Healthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use
- 8 (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA), London, UK
- 9 <sup>2</sup> Antimicrobial Prescribing and Medicines Optimisation, NHS England & NHS Improvement, London,
- 10 UK
- <sup>3</sup> Knowledge and Library Services, United Kingdom Health Security Agency (UKHSA), London, UK
- 12 School of Pharmacy, University of Nottingham, Nottingham, UK
- 13 Corresponding Author
- 14 \*Diane Ashiru-Oredope: diane.ashiru-oredope@ukhsa.gov.uk, +44 2083 276689

**Abstract** 

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

Introduction: Antimicrobial stewardship and patient safety strategies include early intravenous-tooral switch (IVOS) for antimicrobials. Aim: This rapid review aimed to assess and collate IVOS criteria from the literature to achieve safe and effective antimicrobial IVOS in the hospital inpatient adult population. Method: The rapid review follows the PRISMA statement and is registered with PROSPERO. Systematic literature searches were conducted. Articles of adult populations published between 2017-2021 were included. IVOS criteria from UK hospital IVOS policies were categorised to inform the framework synthesis of the literature criteria. Results: IVOS criteria from 45/164 (27%) UK IVOS policies were categorised into a 5-section framework: 1-Timing of IV antimicrobial review, 2-Clinical signs and symptoms, 3-Infection markers, 4-Enteral route, and 5-Infection exclusions. The literature search identified 477 papers, of which 16 were included. The most common timing for review was 48-72 hours from initiation of intravenous antimicrobial (n=5, 30%). Nine studies (56%) stated clinical signs and symptoms must be improving. Temperature was the most frequently mentioned infection marker (n=14, 88%). Endocarditis had the highest mention as an infection exclusion (n=12, 75%). Overall, 33 IVOS criteria were identified to go forward into the Delphi process. Conclusion: Through the rapid review, 33 IVOS criteria were collated and presented within 5 distinct and comprehensive sections. The literature highlighted the possibility of reviewing IVOS before 48-72 hours, and of presenting HR, BP and RR as a combination early warning score criterion. The criteria identified can serve as a starting point of IVOS criteria review for any institution globally, as no country or region limits were applied. Further research is required to achieve consensus on IVOS

criteria from healthcare professionals that manage patients with infections.

What is already known on this topic

- 39 Antimicrobial intravenous-to-oral switch has benefits such as decreased risk of catheter-related
- 40 infections, reduced equipment costs and increased patient mobility and comfort. Acute hospitals
- often develop and implement individualised IVOS policies with varying levels of evidence base.
- What this study adds
- This study provides evidence-based IVOS criteria to standardise practice in hospital settings.
- How this study might affect research, practice or policy
- 45 IVOS criteria can be taken forward through a consensus process with healthcare professionals
- 46 providing the care for hospitalised adult patients and making the decisions regarding infection
- 47 management. In the acute hospital setting, IVOS criteria can be operationalised to promote best
- 48 practice. The criteria can also be considered as part of organisation-wide audits and quality/policy
- 49 incentives.

38

### 1 Introduction

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

Antimicrobial resistance (AMR) is a public health threat, and tackling this threat requires joint efforts at local, national and global levels across all care settings.<sup>2</sup> In the acute hospital care setting. antibiotic consumption is known to promote resistant and multidrug-resistant bacteria leading to healthcare-associated infections.<sup>3</sup> Antibiotic prescribing in England continued to rise in acute hospitals between 2016 and 2020, with specialist hospitals accounting for the highest increase of 31.2%.4 Antimicrobial stewardship (AMS) is defined as a set of strategies to promote the responsible use of antimicrobials<sup>5</sup> for the purpose of protecting public health.<sup>6</sup> Across secondary care, the COVID-19 pandemic had a negative impact on AMS activities, but evidence suggests the pandemic also encouraged collaboration between infection specialists and non-specialists to strengthen activities going forward.<sup>7</sup> Antimicrobial intravenous-to-oral switch (IVOS) has been classified as a "low-hanging fruit" AMS activity; in other words, an attainable AMS strategy despite constrained limitations.8 The literature outlines numerous benefits for IVOS; including decreased risk of catheter-related infections, reduced equipment costs and increased patient mobility and comfort. 9, 10 Additionally. decreased medical equipment usage has the potential to reduce hospital's carbon footprint. 11 In clinically stable patients, studies report that a timely IVOS is safe and of equal efficacy to the full course of IV therapy, <sup>12</sup> with no negative reports on patient outcome. <sup>12</sup> In the United Kingdom (UK), the national Start Smart – Then Focus AMS Toolkit recommends IVOS as an important outcome following review of prescribed antimicrobial within 48-72 hours. Acute hospitals have developed and implemented their own individualised local IVOS policies and there is currently no standardised national criteria recommended for IVOS in the UK. The evidencebase behind the criteria included in the individualised policies is largely unknown. Additionally, they include a variety of criteria themes and nuances in criterion wording. The standardisation of clinical guidance, whether protocols, checklists or other, has led to enhanced patient safety and outcomes and driven improved quality of care. 13-15

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

This rapid review aims to evaluate the evidence-base for IVOS criteria and collate criteria into common themes. This review will subsequently inform a Delphi consensus-gathering process, led by the UK Health Security Agency (UKHSA), to establish standardised, evidence-based, national antimicrobial IVOS criteria. The UK has previously never had nation-wide IVOS criteria available for use by hospitals, this review will form the basis for included IVOS criteria. 2 Method 2.1 Protocol and registration This review was informed by the World Health Organisation<sup>16</sup> and Cochrane<sup>17</sup> rapid review protocols, and follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 item checklist (Supplementary Table S1) and guidance. 18,19 The review protocol is registered with PROSPERO [registration number CRD42022320343].<sup>20</sup> 2.2 Eligibility criteria Articles were included in the review if they were written in English, pertained to an adult (18 years of age or over) population, were clinical trials, review articles, studies or point prevalence studies with a publication date between January 2017 and December 2021, related to the AMS strategy IVOS and with specified IVOS criteria. Studies were excluded if they were case reports and non-studies e.g., conference abstracts, editorials, letters, notes, or related to one particular antimicrobial or specific infection (to exclude non-generalisable criteria). 2.3 Information sources Literature search terms were devised alongside an experienced UKHSA Knowledge and Evidence Specialist (CD). Systematic searches were conducted in OVID Embase and OVID Medline databases. For the initial searches, no start date limit was set, and databases were searched up to 15 December 2021.

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

2.4 Search strategy The defined research question was: What are the criteria necessary to achieve a safe and effective antimicrobial intravenous-to-oral switch in the hospital inpatient adult population? See **Table 1** for database search strategies. 2.5 Selection process Article duplicates were removed on EndNote. One researcher (EH) screened all titles and abstracts for articles relevant to the research question. From this initial screening, Akhloufi et al.'s paper published in 2017 was identified as including an IVOS literature review, <sup>21</sup> thus 2017 onwards became an inclusion criterion to capture evidence published since the most recently identified review. One researcher (EH) screened full articles to ascertain focus of article and identify IVOS criteria. A second researcher (DAO) reviewed the focus themes for accuracy. A second assessment of a random 20% sample of articles dated between the years 2017 and 2021 was conducted by a third researcher (MM). Discrepancies were resolved between two reviewers (EH, MM) with a third reviewed (DAO) as arbiter. 2.6 Data collection process A data extraction Excel spreadsheet was designed with the following column headings: Authors, Year of publication, Title, Journal, Edition, Pages, Month, Article type, DOI, Keywords, Abstract, URL link, Database, Platform, Language, Continent research conducted in, Country/area, Sample size, Population, Focus, Specifics, Healthcare professional mention, Key findings, Exclude/Include, Reason, Additional comments. The Focus heading options included AMS (focus on AMS strategies such as IVOS), Antimicrobial (focus on an individual or class of antimicrobial(s)) or Infection (focus on specific infection). Studies with an AMS focus would further be classified under the Specifics column as General (non-IVOS AMS strategy) or IV Switch (IVOS AMS strategy). The studies in the IV Switch column were further evaluated to ascertain if they included IVOS switch criteria.

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

2.7 Data items The primary outcome sought from the literature was safety of antimicrobial IVOS, defined by measurable IV switch criteria for adults (to include review time, clinical signs and symptoms, infection markers, enteral route, infection exclusions). Additional outcomes were reduced healthcare associated infections, reduced catheter-related infections, reduced hospital length of stay, reduced costs (e.g., drug equipment), reduced staff workload, reduced IV administration errors, increased patient comfort and mobility, improved AMS practice. 2.8 Study risk of bias assessment The included studies were not assessed for internal validity with a risk of bias tool. This differs to the protocol registered on PROSPERO. This decision was agreed by all co-authors and the reasons are: 1) as a rapid review the risk of bias can be omitted, 22 and 2) risk of bias tools become more relevant for studies assessing effectiveness of interventions, whereas this review aimed to identify IVOS criteria to subsequently inform a Delphi consensus-gathering process. 2.9 Synthesis methods There was heterogeneity of study designs and outcome measures. This was expected and was not investigated as outside scope of the rapid review. A framework synthesis on included studies was completed. 2.9.1 Development of framework The framework was derived based on an analysis of IVOS criteria obtained from a sample of UK acute hospital IVOS policies sought though stratified sampling. The target number of IVOS policies was 41 (25%), to include polices from English Trusts and Scottish Health Boards and Northern Ireland and Wales all-country policies. Hospitals from England were selected from an 'All England Trusts and Trust Types' UKHSA datasheet by hospital type (acute – small, acute – medium, acute – large, acute multi-service, acute – specialist, acute – teaching) and region (East of England, London, Midlands, North East and Yorkshire, North West, South East, South West) to ensure representative sampling.

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

English IVOS policies were obtained through internet search or MicroGuide application access. IVOS policies from Scotland's Health Boards were obtained through internet search, and from Northern Ireland and Wales through internet search and email correspondence. An Excel spreadsheet was designed to collate criteria under headings to inform framework sections. 2.10 Certainty of evidence All included studies were peer-reviewed articles, enhancing the certainty of the evidence. Studies were not formally graded. High evidence rating [H] was assigned to high quality evidence such as clinical trials and reviews, and medium evidence rating [M] was assigned to lower quality studies such as prospective studies and point prevalence studies. 3 Results 3.1 Framework synthesis Forty-two acute hospitals (28%, n=148) from England were selected for review of their IVOS policies, two Health Boards (14%, n=14) from Scotland and the All-Wales policy from Wales. No IVOS policy from Northern Ireland was identified at the time of the study period. Overall, 45 (27%, n=164) acute hospital IVOS policies from three UK nations were included for review. IVOS criteria were collated on an Excel spreadsheet under the following 5 framework sections and headings: Review IV within (hours) (Section 1: Timing of IV antimicrobial review); Clinical signs and symptoms (Section 2: Clinical signs and symptoms); Temperature, Heart rate, Blood pressure, Respiratory rate, White cell count, C-reactive protein (Section 3: Infection markers); Gut function, Drug interactions with oral therapy, Allergy to oral therapy (Section 4: Enteral route); and Infection exclusions (Section 5: Infection exclusions) (Supplementary Table S2). 3.2 Study selection Four hundred seventy-seven papers were identified from the literature search. Fifty-nine were nonstudies (e.g., letters, notes, conference abstracts) and therefore excluded. Akhloufi et al.'s IVOS review in 2017<sup>21</sup> led to the timeframe of included papers to be between 2017 and 2021, excluding a

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

further 308 papers. The remaining 110 articles were screened for relevance to the research question by title and abstract. Seventy papers were excluded due to a focus other than AMS. Forty papers were found to be eligible for inclusion and screened by full article. A further 24 papers were excluded as they contained no IVOS criteria or pertained to the paediatric population (n=1). Sixteen papers with IVOS criteria were included for review. See Figure 1 for PRISMA flowchart. The primary outcome of safety of antimicrobial IVOS was identified in eight of the included papers (50%), 12, 21, 23-28 with remaining papers focusing on outcomes classed as additional for the purposes of this study. All papers included measurable IVOS criteria. 3.3 Study characteristics Most published papers were from 2021 (n=4) and 2018 (n=4). The Netherlands had published the most peer-reviewed articles (n=6), followed by two each from the United Kingdom and Australia, and one each from Canada, India, Malaysia, Switzerland, Thailand and Vietnam. Eight papers presented IVOS criteria for use in clinical practice in table format, two in flowchart format and one as text. The remaining five articles did not state how IVOS criteria were presented. The majority (n=11) had a Switch approach, 4 were unknown and one had a Continue approach (Table 2). Switch approach referred to criteria being expressed in terms of 'if patient meets x criteria, consider switch from intravenous to oral therapy', instead of the Continue approach of 'if patient does not meet x criteria, consider continuing intravenous therapy'. 3.4 Results of individual studies Table 2 includes a summary of results of individual studies, including identified IVOS criteria. 3.5 Results of syntheses Eight studies (50%) specified criteria for all 5 sections of the defined framework. Criteria with highest, or over 50%, appearance in the literature, informed by evidence rating was collated. Overall, 33 criteria were identified to go forward into the Delphi process (**Table 3**).

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

3.5.1 Timing of intravenous antimicrobial review Eleven of the 16 included studies (69%) contained criteria pertaining to the timing of IV antimicrobial review. Five of the studies (30%) stated that a review should take place either within (n=3), at (n=1) or after (n=1) the 48-72-hour window from initiation of IV antimicrobial. A clinical trial [H] and a further two studies [M]<sup>26, 28</sup> defined early switch as IVOS taking place within the 48-72 hours. Three studies (19%) stated that a review must occur within (n=1) or after (n=2) 48 hours from initiation of IV antimicrobial. A systematic review [H] investigated early IVOS as being within 48 hours.<sup>29</sup> Three studies (19%) [M] recommended IVOS review to occur after 24 hours.<sup>27, 30, 31</sup> 3.5.2 Clinical signs and symptoms Ten of the 16 studies (63%) included clinical signs and symptoms as a criterion for early IVOS. Nine studies (56%) stated that clinical signs and symptoms must be improving; one of these studies was a (non-systematic) review article [H]. A variance in criterion wording was captured by one study that stated that clinical signs and symptoms must be resolved or improving for safe IVOS. 21 3.5.3 Infection markers The infection markers identified in the literature were temperature, 9, 12, 21, 23, 25-28, 30-35 heart rate. 9, 32-34 blood pressure, 12, 21, 23, 26-28, 31-35 respiratory rate, 9, 12, 32, 33 white cell count 9, 12, 24, 27, 28, 30, 32-34 or absolute neutrophil count<sup>24, 30</sup> and C-reactive protein.<sup>32, 33</sup> 3.5.3.1 Temperature Temperature was the most frequently mentioned infection marker, appearing in 14 of the 16 studies (88%). The most common criterion variance was that temperature must be between the 36-38°C range, appearing in 6 studies (38%). Of these 6 studies, three stated that 36-38°C must have been sustained for the past 24 hours – one of these studies was a clinical trial [H], 12 and one stated for the past 24-48 hours, also a clinical trial [H]. Six studies (38%) [M] did not state a temperature range,

but instead suggested that it must be less than 38°C, <sup>27, 30, 31, 33, 34</sup> or less than 37.6°C. <sup>25</sup> Two studies

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

(13%) did not specify a temperature at all, but instead commented on the need for patient's fever to be resolved or improving, 35 or patient to be afebrile.28 3.5.3.2 Heart rate Four of the 16 studies (25%) included heart rate (HR) as an infection marker for safe IVOS. Two of them (12.5%) stated HR must be below 90 beats/minute – the clinical trial [H] provided no timeframe, whilst the study [M] stated HR must have been sustained for the past 12 hours. 22 3.5.3.3 Blood pressure Eleven of the 16 studies (69%) included blood pressure (BP) as an infection marker for early IVOS. The most common wording for the criterion was BP needed to be stable (n=3, 19%), <sup>28, 31, 32</sup> and BP needed to be stable without inotropics or fluid resuscitation (n=3, 19%). 21, 26, 27 3.5.3.4 Respiratory rate Four of the 16 studies (25%) included respiratory rate (RR) as an infection marker for IVOS. Three studies (19%) stated RR must be below 20 breaths/minute; two of them had no associated timeframe, <sup>9, 33</sup> of which one was a clinical trial [H], <sup>9</sup> and the third, a study [M], stated that the specified RR must have been sustained for the past 24 hours. 32 3.5.3.5 White cell count Nine of the 16 studies (56%) included white cell count (WCC) or absolute neutrophil count within criteria for early IVOS. The preferred wording was divided between WCC must be normalising (n=3, 19%)<sup>9, 27, 34</sup> and WCC must be within 4-12 x10<sup>9</sup>/L (n=3, 19%). Each of these criterion wordings appeared in clinical trials [H]. 9, 12 3.5.3.6 C-reactive protein C-reactive protein (CRP) was the least included infection marker, appearing in only 2 of the 16 studies (13%). Both studies [M] stated that CRP must be normalising for a safe IVOS. 32, 33

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

3.5.4 Enteral route Fourteen of the 16 included studies (88%) had criteria that related to the enteral route. The most common criteria in the literature was that there must be no malabsorption, appearing in 11 of the 16 studies (69%), of which one was a clinical trial [H]<sup>9</sup> and one a review [H].<sup>35</sup> Nine studies (56%) stated that the gut must be functioning and 5 studies (31%) stated the patient must not be vomiting. 3.5.5 Infection exclusions This section included both general information (e.g., infections requiring prolonged IV therapy, deepseated infections) as well as specifically mentioned infections. The infections with highest counts in the literature were endocarditis (n=12, 75%) including in two clinical trials [H]<sup>9, 12</sup> and one review<sup>35</sup> and meningitis (n=8, 50%). Infections with lowest appearance in the literature included mediastinitis (n=4, 25%) and bone and joint infections (n=2, 12.5%). Discussion Early IVOS has numerous advantages compared to continuing intravenous therapy in patients that may be eligible for oral administration. The risk of cannula-related infections and thrombophlebitis would reduce, as would the costs of equipment and staff time. Patient comfort and mobility would be promoted, and the absence of intravenous antimicrobial infusions or injections could result in earlier patient discharge from hospital. 36 Analysis of individualised hospital IVOS policies showcased the variety of IVOS criteria in clinical use. The standardisation of healthcare practice benefits patient safety and outcomes, however it must be evidence-based.<sup>37</sup> Through this rapid review, the literature was systematically searched and 33 IVOS criteria were identified as part of a 5-section framework. 4.1 Criteria sections 4.1.1 Timing of intravenous antimicrobial review The most common timing stated in the literature for IVOS review from initiation of antimicrobial intravenous therapy was 48-72 hours, specifically within the 48-72-hour window. Prior guidance

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

outlines the need to review patients' clinical diagnosis and ongoing need for antibiotics at 48-72 hours. 38, 39 In the UK national Start Smart – Then Focus AMS Toolkit, 38 switching antibiotics from intravenous to oral is one of five recommended choices, alongside stopping antibiotics, changing to a narrower or broader spectrum antibiotic, continuing antibiotic treatment stating time of next review or considering Outpatient Parenteral Antibiotic Therapy. Studies have since questioned whether an earlier review, such as review within 48 hours of intravenous initiation, is warranted. 29, 40 Van den Broek et al. commented that theoretical reasons for an early switch (even within 24 hours) exist; for example, if patient has an intact gastrointestinal tract and the oral antibiotic option has adequate bioavailability (generally data obtained from studies carried out in healthy and/or critically ill patients). However, improved knowledge on antimicrobial bioavailability in the acute stage of infectious illness, when the patient may be febrile and drug pharmacokinetics more unfamiliar, would further strengthen the case for earlier IVOS.<sup>29</sup> 4.1.2 Clinical signs and symptoms Signs as objective manifestations of infectious disease, and symptoms as subjective manifestations, 41 underline the importance of noting improvement, or deterioration, in both the observed response to infection and its management as well as the self-reported accounts of the patient. This rapid review showcases evidence to suggest that the improvement of a patient's signs and symptoms is an important criterion to include for safe IVOS. 21, 24-27 4.1.3 Infection markers Temperature was the predominant infection marker criterion across all studies, with higher evidence for stating a temperature range compared to stating that temperature must be below a certain figure. Infection can elicit thermoregulation in the host, increasing body temperature (fever/hyperthermia) or decreasing it (hypothermia) as in the case of sepsis, 42 thus corroborating the importance of including a temperature range in IVOS criteria. Despite temperature being a vital marker of infection, normothermia, categorised as 36.1-38°C, has been associated with infection and higher patient mortality than hyperthermia.<sup>43</sup> Normothermia

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

therefore does not exclude the need for antibiotics; and if antibiotics are given, normothermia would not necessarily mean that a switch from intravenous to oral therapy should be made. Other infection markers, to include physiological and inflammatory parameters, 43 must be considered to ensure any IVOS decision is safe. The National Early Warning Score (NEWS) developed by the UK Royal College of Physicians is a recognised clinical assessment tool for use in acute hospital and ambulance settings. It was first published in 2012 with a second version, NEWS2, released in 2017. The tool 'improves the detection and response to clinical deterioration in adult patients and is a key element of patient safety and improving patient outcomes'. 13,44 NEWS2 aggregates individual scores from the following physiological parameters: respiration rate, oxygen saturation, systolic blood pressure, pulse rate, level of consciousness or new confusion, and temperature. Certain parameters overlap with the IVOS criteria found in the literature, notably temperature, but also respiration/respiratory rate and blood pressure. The marker named heart rate in this rapid review is specified as pulse rate in NEWS2. For each marker of HR, BP and RR, the literature showcased a variety of nuances in criteria wording. Some criteria, but not all, specify marker values with or without a particular timeframe for which the specified infection marker must be sustained for; e.g., HR below 90 beats/min for the past 12 hours. The benefit of the NEWS2 score is that ranges, not merely single values, are used to assess clinical deterioration. Additionally, it is a tool endorsed for use in patients with acute infection or at risk of infection and widely implemented across UK NHS hospitals. 13 Presenting separate criteria for HR, BP and RR is one way to achieve safe IVOS, 12, 21, 23, 26-28 however presenting them combined into a NEWS2 scoring criterion would offer an alternative evidence-based way to achieve safe IVOS. Other countries have also adopted Early Warning Scores (EWS) to identify patients at risk of deterioration, especially from infection, thus IVOS criteria in other countries could consider EWS as a criterion. In Canada, for example, the Hamilton Early Warning Score of similar prognostic accuracy to

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

NEWS2 is used. 45 In the United States of America, a variety of tools exist with the NEWS tool considered most accurate to identify patients at high risk of mortality.<sup>46</sup> 4.1.4 Enteral route This section of the framework is concerned with maximising enteral antibiotic absorption from the gastrointestinal tract (GIT), and hence maximising antibiotic bioavailability and therapeutic action. Antibiotic administration via the intravenous route achieves 100% bioavailability. 36 Some antibiotics are known to have good oral bioavailability, for example clindamycin, doxycycline, linezolid and metronidazole have over 90% oral bioavailability. 36, 47 The literature outlines numerous criteria to ensure a switch to oral administration, or indeed to enteral administration to include use of enteral tubes, achieves as close to 100% bioavailability as practicable. The criteria centre on patient characteristics, predominantly in relation to their GIT function e.g., no malabsorption present, but also in relation to their level of alertness e.g., patient is not unconscious. The latter resonates with one of the physiological scores included in the NEWS2 (level of consciousness or new confusion scoring), <sup>13</sup> further promoting inclusion of EWS as a combination criterion for safe IVOS. The literature includes no mention of antibiotic pharmacological properties such as antibiotic bioavailability, nor the need to review drug interactions between oral antibiotic options and any other medication the patient may be taking or to check for allergies. It is worth noting that these criteria do appear in the sample of acute hospital IVOS policies used to inform the framework analysis (Supplementary Table S2). 4.1.5 Infection exclusions Over the years, randomised controlled trials have been undertaken comparing treatment arms of prolonged intravenous antibiotic courses and shorter courses. The research has demonstrated equal outcomes between treatment arms for infections such as community-acquired pneumonia and neutropenic fever. 48 These results have enabled change in clinical practice and advancement in AMS.

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

However, not all infections have the evidence to make them eligible for early IVOS. This section of the framework provides a caveat around certain infections when making early IVOS decisions. Endocarditis was the infection exclusion with highest appearance in the literature. The POET trial enrolled patients with left-sided endocarditis and compared full course intravenous therapy versus oral switch after a minimum of 10 days intravenous therapy. IVOS was found to be noninferior in terms of treatment failure at one year compared to full intravenous therapy. 49 However, the timing of IVOS (after at least 10 days of intravenous therapy) was much later than the timing for IVOS proposed in the included literature for this rapid review. Considering the current available evidence, endocarditis may remain as an infection exclusion within IVOS criteria. Bone and joint infections appeared only twice in the literature, in papers published in 2018<sup>34</sup> and 2019. 30 Around that time, the OVIVA trial investigated early IVOS for bone and joint infections and concluded that oral antibiotic treatment was noninferior to intravenous treatment. Trial IVOS decisions were led by specialist teams, 50 so it remains to be said that in the standardisation process of IVOS criteria, which also serves to equip non-specialist teams, professional judgment regarding when to refer patients for specialist input remains important in IVOS decision-making. 4.2 Strengths and limitations A strength of this study includes a systematic literature search being undertaken to capture papers relevant to IVOS AMS strategy. Papers were not limited by country or region, thus the criteria identified can serve as a starting point for any institution globally. Two researchers (EH, DAO) were involved in reviewing themes and included papers, with a separate researcher (MM) undertaking a second assessment of a random sample of papers. A limitation is that non-English papers were excluded, potentially discounting research on IVOS criteria conducted in non-English speaking nations. During the study period, the authors were not aware of a published validated rapid review reporting protocol. 51 However, the WHO and Cochrane approaches to rapid reviews were taken into consideration and the authors followed through the PRISMA reporting guidelines.

# 5 Conclusion

The benefits of early IVOS include reduced risk of healthcare-associated and catheter-related infections, reduced costs, staff workload and hospital length of stay, and increased patient mobility and comfort. Individual hospital polices contain variable IVOS criteria with an unknown evidence-base. This rapid review has identified and collated 33 evidence-based IVOS criteria from the literature and presented them within 5 distinct and comprehensive sections.

Further research is required to achieve a national consensus on IVOS criteria from healthcare professionals providing the care for hospitalised adult patients and making the decisions regarding infection management. In the acute hospital setting, operationalisation of IVOS criteria as a tool to promote best practice needs to be explored and must take into consideration the roles and strengths that a multidisciplinary team brings to AMS.

6 Author contributions 386 387 Conceptualisation: DAO, EH. Methodology: EH undertook framework analysis, literature review and 388 drafted paper, CD contributed to literature searches, MM undertook the random second assessment 389 of articles, DAO validated aspects of methodology and supervised the review. All authors reviewed 390 and approved final version. Funding 391 392 This research was funded by the UK Health Security Agency. The views expressed in this publication 393 are those of the author(s) and not necessarily those of the UK Health Security Agency. **Declarations** 394 395 None to declare. Ethics approval 396 397 This study does not involve human participants. 10 Data availability statement 398 399 All data relevant to the study are included in the article or uploaded as supplemental information.

### 11 References

400

- 401 1. Murray CJL, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet*, 2022. 399(10325): p. 629-655.
- O'Neill J. Tackling drug-resistant infectios globally: final report and recommendations. 2016,
   [Date accessed: August 2022]: <a href="https://apo.org.au/sites/default/files/resource-files/2016-">https://apo.org.au/sites/default/files/resource-files/2016-</a>
   O5/apo-nid63983.pdf.
- 406 3. European Centre for Disease Prevention and Control. Summary of the latest data on antibiotic consumption in the European Union. 2017, [Date accessed: August 2022]: https://www.ecdc.europa.eu/sites/default/files/documents/Final\_2017\_EAAD\_ESAC-Net\_Summary-edited%20-%20FINALwith%20erratum.pdf.
- 4. UK Health Security Agency. English surveillance programme for antimicrobial utilisation and
   411 resistance (ESPAUR) report. 2021, [Date accessed: August 2022]:
   412 https://www.gov.uk/government/publications/english-surveillance-programme-
- 413 antimicrobial-utilisation-and-resistance-espaur-report.
- 5. Dyar OJ, Huttner B, Schouten J, et al. What is antimicrobial stewardship? Clin Microbiol Infect, 2017. 23(11): p. 793-798.
- Viasus D, Vecino-Moreno M, De La Hoz JM, et al. Antibiotic stewardship in community-acquired pneumonia. *Expert Rev Anti Infect Ther*, 2017. 15(4): p. 351-359.
- 418 7. Ashiru-Oredope D, Kerr F, Hughes S, et al. Assessing the impact of COVID-19 on antimicrobial stewardship activities/programs in the United Kingdom. *Antibiotics*, 2021. 10(2): p. 110.
- 420 8. Goff DA, Bauer KA, Reed EE, et al. Is the "low-hanging fruit" worth picking for antimicrobial stewardship programs? Clin Infect Dis, 2012. 55(4): p. 587-592.
- Nguyen AD, Mai-Phan TA, Tran MH, et al. The effect of early switching from intravenous to
   oral antibiotic therapy: a randomized controlled trial. J Pharm Pharmacogn Res, 2021. 9(5):
   p. 695-703.
- Schuts EC, Hulscher M, Mouton JW, et al. Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. Lancet Infect Dis, 2016. 16(7): p. 847-856.
- Tennison I, Roschnik S, Ashby B, et al. Health care's response to climate change: a carbon footprint assessment of the NHS in England. The Lancet Planetary Health, 2021. 5(2): p. e84-e92.
- 431 12. Wongkamhla T, Khan-Asa B, Tongsai S, et al. Infectious Disease Team Review Using
   432 Antibiotic Switch and Discharge Criteria Shortens the Duration of Intravenous Antibiotic: A
   433 Single-Center Cluster-Randomized Controlled Trial in Thailand. Open Forum Infect Dis, 2020.
   434 7(12): p. ofaa539.
- 435 13. Royal College of Physicians. National Early Warning Score (NEWS) 2: Standardising the assessment of acute-illness severity in the NHS. 2017, [Date accessed: August 2022]: https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2.
- 438 14. ACOG. Clinical guidelines and standardization of practice to improve outcomes. Committee opinion no. 629. *Obstet Gynecol*, 2015. 125(4): p. 1027-1029.
- Stone J. Defining standardization and personalized care, Medical GPS, Editor. 2020, [Date accessed: August 2022]: <a href="https://blog.medicalgps.com/defining-standardization-and-personalized-care/">https://blog.medicalgps.com/defining-standardization-and-personalized-care/</a>.
- Tricco AC, Langlois E, Straus SE, et al., Rapid reviews to strengthen health policy and systems: a practical guide. 2017: World Health Organization.
- Garritty C, Gartlehner G, Nussbaumer-Streit B, et al. Cochrane Rapid Reviews Methods
   Group offers evidence-informed guidance to conduct rapid reviews. Journal of clinical
   epidemiology, 2021. 130: p. 13-22.
- 448 18. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev, 2021. 10(1): p. 1-11.

- 450 19. Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. *BMJ*, 2021. 372.
- Harvey E and Ashiru-Oredope D. Criteria to achieve safe and effective antimicrobial intravenous to oral switch in hospitalised adults: a rapid review. *PROSPERO*, 2022. CRD42022320343.
- 455 21. Akhloufi H, Hulscher M, Melles DC, et al. Development of operationalized intravenous to oral antibiotic switch criteria. *J Antimicrob Chemother*, 2017. 72(2): p. 543-546.
- Haby MM, Chapman E, Clark R, et al. What are the best methodologies for rapid reviews of the research evidence for evidence-informed decision making in health policy and practice: a rapid review. Health Syst Policy Res, 2016. 14(1): p. 1-12.
- 460 23. Akhloufi, H, M Hulscher, CP Van Der Hoeven, et al. A clinical decision support system
  461 algorithm for intravenous to oral antibiotic switch therapy: Validity, clinical relevance and
  462 usefulness in a three-step evaluation study. *Journal of Antimicrobial Chemotherapy*, 2018.
  463 73(8): p. 2201-2206.
- Berrevoets, MAH, JHLW Pot, AE Houterman, et al. An electronic trigger tool to optimise intravenous to oral antibiotic switch: A controlled, interrupted time series study.

  Antimicrobial Resistance and Infection Control, 2017. 6(1) (no pagination).
- 467 25. Kan T, Kwan D, Chan T, et al. Implementation of a Clinical Decision Support Tool to Improve 468 Antibiotic IV-to-Oral Conversion Rates at a Community Academic Hospital. Can J Hosp 469 Pharm, 2019. 72(6): p. 455-461.
- Khumra S, Mahony AA, Bergen PJ, et al. Evaluation of intravenous to oral antimicrobial switch at a hospital with a tightly regulated antimicrobial stewardship program. Br J Clin Pharmacol, 2021. 87(8): p. 3354-3358.
- Tejaswini YS, Challa SR, Nalla KS, et al. Practice of intravenous to oral conversion of
   antibiotics and its influence on length of stay at a tertiary care hospital: A prospective study.
   J Clin Diagn Res, 2018. 12(3): p. FC01-FC04.
- 476 28. Van Den Bosch CMA, Hulscher MEJL, Akkermans RP, et al. Appropriate antibiotic use reduces length of hospital stay. *J Antimicrob Chemother*, 2017. 72(3): p. 923-932.
- van den Broek AK, Prins JM, Visser CE, et al. Systematic review: the bioavailability of orally administered antibiotics during the initial phase of a systemic infection in non-ICU patients.

  BMC Infect Dis, 2021. 21(1) (no pagination).
- 481 30. Gurtler N, Erba A, Giehl C, et al. Appropriateness of antimicrobial prescribing in a Swiss tertiary care hospital: a repeated point prevalence survey. Swiss Med Wkly, 2019. 149: p. w20135.
- 484 31. Mouwen AMA, Dijkstra JA, Jong E, et al. Early switching of antibiotic therapy from
  485 intravenous to oral using a combination of education, pocket-sized cards and switch advice:
  486 A practical intervention resulting in reduced length of hospital stay. Int J Antimicrob Agents,
  487 2020. 55(1): p. 105769.
- 488 32. Dutey-Magni PF, Gill MJ, McNulty D, et al. Feasibility study of hospital antimicrobial stewardship analytics using electronic health records. *JAC Antimicrob Resist*, 2021. 3(1) (no pagination).
- 491 33. Powell N, McGraw-Allen K, Menzies A, et al. Identifying antibiotic stewardship interventions 492 to meet the NHS England CQUIN: An evaluation of antibiotic prescribing against published 493 evidence-based antibiotic audit tools. *J R Coll Physicians Lond*, 2018. 18(4): p. 276-281.
- Sze WT and Kong MC. Impact of printed antimicrobial stewardship recommendations on
   early intravenous to oral antibiotics switch practice in district hospitals. *Pharm Pract*, 2018.
   16(2): p. 855.
- 497 35. McCarthy K and Avent M. Oral or intravenous antibiotics? Aust Prescr, 2020. 43(2): p. 45-48.
- 498 36. Cyriac JM and James E. Switch over from intravenous to oral therapy: a concise overview. *J Pharmacol Pharmacother*, 2014. 5(2): p. 83-87.

Pharmacol Pharmacother, 2014. 5(2): p. 83-87.

- World Medical Association. WMA resolution on standardiation in medical practice and patient safety, in *Current Policies*,, Policy, Editor. 2022, [Date accessed: August 2022]: <a href="https://www.wma.net/policies-post/wma-resolution-on-standardisation-in-medical-practice-and-patient-safety/">https://www.wma.net/policies-post/wma-resolution-on-standardisation-in-medical-practice-and-patient-safety/</a>.
- 38. Public Health England. Start Smart Then Focus: Antimicrobial stewardship toolkit for
   505 English hospitals. 2015, [Date accessed: August 2022]:
   506 <a href="https://www.gov.uk/government/publications/antimicrobial-stewardship-start-smart-then-focus">https://www.gov.uk/government/publications/antimicrobial-stewardship-start-smart-then-focus</a>.
- Nathwani D, Lawson W, Dryden M, et al. Implementing criteria-based early switch/early
   discharge programmes: A European perspective. Clin Microbiol Infect, 2015. 21(Supplement
   p. S47-S55.
- 511 40. Cunha CB. Antibiotic stewardship program perspective: Oral antibiotic therapy for common infectious diseases. *Med Clin*, 2018. 102(5): p. 947-954.
- 513 41. King LS. Signs and symptoms. *JAMA*, 1968. 206(5): p. 1063-1065.
- 514 42. Schieber AMP and Ayres JS. Thermoregulation as a disease tolerance defense strategy.
  515 Pathog Dis, 2016. 74(9).
- 516 43. Schuttevaer R, Brink A, Alsma J, et al. The association of body temperature with antibiotic therapy and mortality in patients attending the emergency department with suspected infection. Eur J Emerg Med, 2021. 28(6): p. 440.
- 519 44. NHS England. National Early Warning Score (NEWS). 2022, [Date accessed: August 2022]: 520 <a href="https://www.england.nhs.uk/ourwork/clinical-policy/sepsis/nationalearlywarningscore/">https://www.england.nhs.uk/ourwork/clinical-policy/sepsis/nationalearlywarningscore/</a>.
- Fernando SM, Fox-Robichaud AE, Rochwerg B, et al. Prognostic accuracy of the Hamilton Early Warning Score (HEWS) and the National Early Warning Score 2 (NEWS2) among hospitalized patients assessed by a rapid response team. *Critical Care*, 2019. 23(1): p. 1-8.
- 524 46. Liu VX, Lu Y, Carey KA, et al. Comparison of early warning scoring systems for hospitalized patients with and without infection at risk for in-hospital mortality and transfer to the intensive care unit. *JAMA network open*, 2020. 3(5): p. e205191-e205191.
- Quinn NJ, Sebaaly JC, Patel BA, et al. Effectiveness of oral antibiotics for definitive therapy of
   non-Staphylococcal Gram-positive bacterial bloodstream infections. Therapeutic Advances in
   Infectious Disease, 2019. 6: p. 2049936119863013.
- Wald-Dickler N and Spellberg B. Short-course antibiotic therapy—replacing constantine units with "shorter is better". 2019, Oxford University Press US. p. 1476-1479.
- 532 49. Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med, 2019. 380(5): p. 415-424.
- 534 50. Li H-K, Rombach I, Zambellas R, et al. Oral versus intravenous antibiotics for bone and joint infection. *N Engl J Med*, 2019. 380(5): p. 425-436.
- 536 51. Stevens A, Garritty C, Hersi M, et al. Developing PRISMA-RR, a reporting guideline for rapid reviews of primary studies (Protocol). equator network, 2018.

#### Table 1. OVID Embase and OVID Medline search strategies


#### **OVID Embase**

- 1. exp \*antiinfective agent/
- 2. exp \*anti-infective therapy/
- 3. exp \*antimicrobial therapy/
- 4. antimicrobial stewardship.tw.
- 5. 1 or 2 or 3 or 4
- 6. ((IV or intravenous or early or antibiotic or oral) adj3 switch\*).tw.
- 7. IVOS\*.tw.
- 8. 6 or 7
- 9. 5 and 8
- 10 limit 9 to (human and english language)

### **OVID Medline**

- 1. Anti-Infective Agents/
- 2. Antimicrobial Stewardship/
- 3. 1 or 2
- 4. ((IV or intravenous or early or antibiotic or oral) adj3 switch\*).tw.
- 5. IVOS\*.tw.
- 6. 4 or 5
- 7. 3 and 6

Figure 1. PRISMA flowchart of the literature search and rapid review



medRxiv preprint doi: https://doi.org/10.1101/2022.09.01.22279505; this version posted September 2, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

Table 2. Summary of results of individual studies

Article	Outcome sought	Evidence rating	Layout	Approach	Timing of IV antimicrobial review (h)	Clinical signs and symptoms	Infection markers	Enteral route	Infection exclusions
Akhlou fi H et al., 2017 <sup>1</sup>	Safety of IVOS	[M]	Table	Switch	After 48-72	Resolved or improving	Temperature 36-38 °C, BP stable without inotropics or fluid resuscitation	Functioning gut; no malabsorption, short bowel syndrome, severe gastroparesis, ileus, continuous nasogastric suction, vomiting; patient is cooperative	Infections requiring high concentration; severe sepsis, necrotising fasciitis, bacteraemia, endovascular infection, CNS infection
Akhlou fi et al., 2018 <sup>2</sup>	Safety of IVOS	[M]	Table	Switch	-	-	Temperature 36-38 °C (past 24h), BP >90 mmHg	-	-
Berrev oets et al., 2017 <sup>3</sup>	Safety of IVOS	[M]	Table	Switch	At 48-72	Improving	ANC >0.5 x10 <sup>9</sup> /L	Functioning gut; no malabsorption, short bowel syndrome, vomiting, nausea; patient tolerates oral route	Infections requiring prolonged IV therapy; necrotising fasciitis, bacteraemia, endocarditis, meningitis, neutropenia, abscess, mediastinitis, infection of foreign bodies, cystic fibrosis, empyema

Dutey- Magni PF et al., 2021 <sup>4</sup>	Improved AMS practice	[M]	Text	Switch	-	Improving	Temperature 36-38 °C (past 24h), HR <90 beats/min (past 12h), BP stable (past 24h), RR <20 breaths/min (past 24h), WCC 4-12 x10 <sup>9</sup> /L or normalising, CRP normalising	Functioning gut; no malabsorption; patient tolerates oral/enteral feeding	Deep-seated, high- risk infections and infections requiring high concentration; necrotising soft tissue, bacteraemia, endocarditis, meningitis, neutropenia, abscess, mediastinitis, foreign body infection, cystic fibrosis, bronchiectasis, osteomyelitis, septic arthritis, pneumonia
Gurtle r N et al., 2019 <sup>5</sup>	Improved AMS practice	[M]	Unknown	Switch	After 24	Improving	Temperature <38 °C, ANC >0.5 x10 <sup>9</sup> /L	Functioning gut	Endocarditis, abscess, bone/joint infection
Kan T et al., 2019 <sup>6</sup>	Safety of IVOS Improved AMS practice	[M]	Table	Switch	After 48	Improving	Temperature <37.6 °C (past 24h)	Functioning gut; not nil by mouth; patient tolerates oral route	Bacteraemia, endocarditis, meningitis, neutropenia
Khumr a S et al., 2021 <sup>7</sup>	Safety of IVOS Improved AMS practice	[M]	Flowchart	Continue	Within 48-72	Improving	Temperature 36-38 °C, BP stable without inotropics or fluid resuscitation	No malabsorption, short bowel syndrome, ileus, vomiting, severe diarrhoea, not nil by mouth; patient tolerates	Deep-seated infections; necrotising soft tissue, bacteraemia, endocarditis, meningitis, neutropenia, abscess, implant of prosthesis

								oral/enteral feeding	infection, empyema, osteomyelitis, septic arthritis
McCar thy K & Avent M, 2020 <sup>8</sup>	Improved AMS practice	[H]	Table	Switch	-	Improving	Fever resolved or improving, no unexplained haemodynamic instability	No malabsorption; patient tolerates oral route	Infections requiring high concentration and prolonged IV therapy; endocarditis, meningitis
Mouw en AMA et al., 2020 <sup>9</sup>	Improved AMS practice  Reduced hospital length of stay	[M]	Flowchart	Switch	After 24	Improving	Temperature <38 °C (past 24h), BP stable (past 24h)	No malabsorption, vomiting, diarrhoea; patient tolerates oral route	-
Nguye n AD et al., 2021 <sup>10</sup>	Effective- ness of IVOS  Reduced hospital length of stay  Reduced costs	[H]	Unknown	Unknown	Within 48-72	-	Temperature 36-38 °C (past 24-48h), HR <90 beats/min, RR <20 breaths/min, WCC normalising	No malabsorption, ileus, severe diarrhoea, gastrectomy, dysphagia; patient tolerates oral route, not unconscious	Septic shock, cellulitis, bacteraemia, endocarditis, meningitis, immunodeficiency, prosthetic material infection, osteomyelitis, pneumonia, cirrhosis
Powell N et al., 2018 <sup>11</sup>	Improved AMS practice	[M]	Table	Switch	-	-	Temperature <38 °C (past 24h), HR <100 beats/min (past 12h), BP >100	Functioning gut; no malabsorption; patient tolerates oral route	Deep-seated infections; bacteraemia, endocarditis, meningitis,

							mmHg, RR <20 breaths/min, WCC 4-12 x10 <sup>9</sup> /L, CRP normalising		neutropenia, abscess, mediastinitis, prosthetic device or foreign body infection, cystic fibrosis, bronchiectasis, empyema, osteomyelitis, septic arthritis, pneumonia
Sze WT & Kong MC, 2018 <sup>12</sup>	Improved AMS practice  Reduced hospital length of stay  Reduced costs	[M]	Unknown	Unknown	After 48	Improving	Temperature <38 °C (past 24h), HR <100 beats/min, BP >90 mmHg, WCC normalising	Functioning gut; no malabsorption, vomiting, severe diarrhoea, swallowing disorder, active bleeding, not nil by mouth; patient tolerates oral route, not unconscious	Infections requiring prolonged IV therapy; sepsis, bacteraemia, endocarditis, meningitis, immunodeficiency, abscess, cystic fibrosis, empyema, bone/joint infection, orbital cellulitis, endophthalmitis, melioidosis
Tejasw ini YS et al., 2018 <sup>13</sup>	Safety of IVOS  Improved AMS practice  Reduced hospital length of stay	[M]	Unknown	Unknown	After 24	Improving	Temperature <38 °C (past 24h), BP stable without inotropics or fluid resuscitation, WCC normalising	No malabsorption, active bleeding; patient tolerates oral/enteral feeding	Infections requiring prolonged IV therapy; sepsis, bacteraemia, endocarditis, CNS infection, immunodeficiency, osteomyelitis, septic arthritis, fungemia, endophthalmitis, orbital cellulitis

	Reduced								
van den Bosch CMA et al., 2017 <sup>14</sup>	costs Safety of IVOS Reduced hospital length of stay Reduced costs	[M]	Table	Switch	Within 48-72	-	Afebrile, BP stable, WCC 4- 12 x10 <sup>9</sup> /L	Functioning gut; no malabsorption; patient tolerates oral route	Soft tissue infections, bacteraemia, endocarditis, meningitis, neutropenia, abscess, mediastinitis, foreign body infection, cystic fibrosis, empyema, osteomyelitis, arthritis, Legionella
van den Broek AK et al., 2021 <sup>15</sup>	Improved AMS practice	[H]	Unknown	Unknown	Within 48	-	-	-	pneumonia -
Wong kamhl a T et al., 2020 <sup>16</sup>	Safety of IVOS  Reduced hospital length of stay	[H]	Table	Switch	-	-	Temperature 36-38 °C (past 24h), BP >100 mmHg, RR <22 breaths/min, WCC 4-12 x10 <sup>9</sup> /L	Functioning gut; patient tolerates oral route	Sepsis, endocarditis, CNS infection, neutropenia

## Table 2 References

- 1. Akhloufi H, Hulscher M, Melles DC, et al. Development of operationalized intravenous to oral antibiotic switch criteria. *J Antimicrob Chemother*, 2017. 72(2): p. 543-546.
- 2. Akhloufi, H, M Hulscher, CP Van Der Hoeven, et al. A clinical decision support system algorithm for intravenous to oral antibiotic switch therapy: Validity, clinical relevance and usefulness in a three-step evaluation study. *Journal of Antimicrobial Chemotherapy*, 2018. 73(8): p. 2201-2206.
- 3. Berrevoets, MAH, JHLW Pot, AE Houterman, et al. An electronic trigger tool to optimise intravenous to oral antibiotic switch: A controlled, interrupted time series study.

  Antimicrobial Resistance and Infection Control, 2017. 6(1) (no pagination).
- 4. Dutey-Magni PF, Gill MJ, McNulty D, et al. Feasibility study of hospital antimicrobial stewardship analytics using electronic health records. *JAC Antimicrob Resist*, 2021. 3(1) (no pagination).
- 5. Gurtler N, Erba A, Giehl C, et al. Appropriateness of antimicrobial prescribing in a Swiss tertiary care hospital: a repeated point prevalence survey. Swiss Med Wkly, 2019. 149: p. w20135.
- 6. Kan T, Kwan D, Chan T, et al. Implementation of a Clinical Decision Support Tool to Improve Antibiotic IV-to-Oral Conversion Rates at a Community Academic Hospital. *Can J Hosp Pharm*, 2019. 72(6): p. 455-461.
- 7. Khumra S, Mahony AA, Bergen PJ, et al. Evaluation of intravenous to oral antimicrobial switch at a hospital with a tightly regulated antimicrobial stewardship program. Br J Clin Pharmacol, 2021. 87(8): p. 3354-3358.
- 8. McCarthy K and Avent M. Oral or intravenous antibiotics? Aust Prescr, 2020. 43(2): p. 45-48.
- 9. Mouwen AMA, Dijkstra JA, Jong E, et al. Early switching of antibiotic therapy from intravenous to oral using a combination of education, pocket-sized cards and switch advice: A practical intervention resulting in reduced length of hospital stay. Int J Antimicrob Agents, 2020. 55(1): p. 105769.
- 10. Nguyen AD, Mai-Phan TA, Tran MH, et al. The effect of early switching from intravenous to oral antibiotic therapy: a randomized controlled trial. J Pharm Pharmacogn Res, 2021. 9(5): p. 695-703.
- 11. Powell N, McGraw-Allen K, Menzies A, et al. Identifying antibiotic stewardship interventions to meet the NHS England CQUIN: An evaluation of antibiotic prescribing against published evidence-based antibiotic audit tools. *J R Coll Physicians Lond*, 2018. 18(4): p. 276-281.
- 12. Sze WT and Kong MC. Impact of printed antimicrobial stewardship recommendations on early intravenous to oral antibiotics switch practice in district hospitals. *Pharm Pract*, 2018. 16(2): p. 855.
- 13. Tejaswini YS, Challa SR, Nalla KS, et al. Practice of intravenous to oral conversion of antibiotics and its influence on length of stay at a tertiary care hospital: A prospective study. *J Clin Diagn Res*, 2018. 12(3): p. FC01-FC04.
- 14. Van Den Bosch CMA, Hulscher MEJL, Akkermans RP, et al. Appropriate antibiotic use reduces length of hospital stay. *J Antimicrob Chemother*, 2017. 72(3): p. 923-932.
- van den Broek AK, Prins JM, Visser CE, et al. Systematic review: the bioavailability of orally administered antibiotics during the initial phase of a systemic infection in non-ICU patients. BMC Infect Dis, 2021. 21(1) (no pagination).
- Wongkamhla T, Khan-Asa B, Tongsai S, et al. Infectious Disease Team Review Using Antibiotic Switch and Discharge Criteria Shortens the Duration of Intravenous Antibiotic: A Single-Center Cluster-Randomized Controlled Trial in Thailand. Open Forum Infect Dis, 2020. 7(12): p. ofaa539.

Table 3. Criteria from rapid review (n=33) to go forward into Delphi process

Criteria	Number of papers n, (%)	Evidence rating
1. Timing of IV antimicrobial review		
a. Review antimicrobial within 48 hours	1 (6)	[H]
b. Review antimicrobial within 48-72 hours	3 (19)	[M] x2, [H]
2. Clinical signs and symptoms		
a. Clinical signs and symptoms should be improving	9 (56)	[M] x8, [H]
3. Infection markers		
a. Temperature should be between 36-38°C	2 (13)	[M] x2
b. Temperature should be between 36-38 °C past <b>24 hours</b>	3 (19)	[M] x2, [H]
c. Heart rate should be below 90 beats per minute	1 (6)	[H]
d. Heart rate should be below 90 beats per minute for past <b>12 hours</b>	1 (6)	[M]
e. Blood pressure should be stable	1 (6)	[M]
f. Blood pressure stable for past <b>24 hours</b>	2 (13)	[M] x2
g. Respiratory rate should be below 20 breaths per minute	2 (13)	[M], [H]
h. Respiratory rate should be below 20 breaths per minute for past 24 hours	1 (6)	[M]
i. White cell count should be normalising	3 (19)	[M] x2, [H]
j. White cell count should be between 4 and 12 x10^9/L	3 (19)	[M] x2, [H]
k. White cell count should be between 4 and 12 x10^9/L or normalising	1 (6)	[M]
I. C-reactive protein should be normalising	2 (13)	[M] x2
4. Enteral route		
a. Gastrointestinal tract must be functional	9 (57)	[M] x8, H
b. Patient can tolerate/ swallow oral option	9 (57)	[M] x6, [H]x3
c. No evidence of malabsorption	11 (69)	[M] x9, [H] x2
d. No vomiting	5 (31)	[M] x5
5. Infection exclusions		
a. Deep-seated infections	3 (19)	[M] x3
b. Infections requiring high tissue concentration	3 (19)	[M] x2, [H]
c. Infections requiring prolonged IV therapy	4 (25)	[M] x3, [H]

d. Critical infection with high risk of mortality	1 (6)	[M]
e. Endocarditis	12 (75)	[M] x9, [H] x3
f. Meningitis	9 (56)	[M] x7, [H] x2
g. Bacteraemia, including Staph. aureus	9 (56)	[M] x9
h. Immunocompromised	3 (19)	
i. Abscess	7 (44)	[M] x7
j. Severe or necrotising soft tissue infections	5 (31)	[M] x5
k. Infections of foreign bodies	6 (38)	[M] x5, [H]
I. Osteomyelitis	6 (38)	[M] x5, [H]
m. Septic arthritis	5 (31)	[M] x5
n. Empyema	5 (31)	[M] x5